(NASDAQ: ROIV) Roivant Sciences's forecast annual revenue growth rate of 38.44% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Roivant Sciences's revenue in 2024 is $123,241,000.On average, 7 Wall Street analysts forecast ROIV's revenue for 2024 to be $103,753,479,119, with the lowest ROIV revenue forecast at $99,763,735,543, and the highest ROIV revenue forecast at $109,409,712,235. On average, 7 Wall Street analysts forecast ROIV's revenue for 2025 to be $143,274,584,791, with the lowest ROIV revenue forecast at $107,983,364,804, and the highest ROIV revenue forecast at $195,175,902,653.
In 2026, ROIV is forecast to generate $282,306,390,360 in revenue, with the lowest revenue forecast at $189,373,811,410 and the highest revenue forecast at $440,797,765,282.